SHINE Secures $263M DOE Loan for First U.S. Commercial Mo-99 Isotope Facility

Event summary

  • SHINE received a conditional $263M loan commitment from the DOE to complete Chrysalis, the world's largest medical isotope production facility.
  • Chrysalis will establish the first domestic commercial supply of molybdenum-99 (Mo-99), currently imported from aging reactors in Europe, South Africa, and Australia.
  • The facility uses fusion technology and recycled liquid uranium targets to reduce waste and operating costs.
  • Chrysalis is expected to support 200 construction jobs and 150 permanent operations positions in Janesville, Wisconsin.

The big picture

SHINE's Chrysalis project represents a strategic shift in medical isotope production, moving from aging international reactors to a domestic, fusion-powered facility. This aligns with broader trends in advanced manufacturing and supply chain resilience, particularly in critical healthcare materials. The $263M loan underscores the U.S. government's commitment to securing domestic production of essential medical isotopes, reducing logistical vulnerabilities, and demonstrating commercial-scale fusion technology.

What we're watching

Regulatory Approval
Whether SHINE can satisfy the technical, legal, environmental, and financial conditions to finalize the DOE loan.
Execution Risk
The pace at which Chrysalis can become operational and displace existing global Mo-99 supply chains.
Market Impact
How the establishment of a domestic Mo-99 supply will affect pricing and availability for medical procedures.